Literature DB >> 29488768

Separating T Cell Targeting Components onto Magnetically Clustered Nanoparticles Boosts Activation.

Alyssa K Kosmides, Kevin Necochea, John W Hickey, Jonathan P Schneck.   

Abstract

T cell activation requires the coordination of a variety of signaling molecules including T cell receptor-specific signals and costimulatory signals. Altering the composition and distribution of costimulatory molecules during stimulation greatly affects T cell functionality for applications such as adoptive cell therapy (ACT), but the large diversity in these molecules complicates these studies. Here, we develop and validate a reductionist T cell activation platform that enables streamlined customization of stimulatory conditions. This platform is useful for the optimization of ACT protocols as well as the more general study of immune T cell activation. Rather than decorating particles with both signal 1 antigen and signal 2 costimulus, we use distinct, monospecific, paramagnetic nanoparticles, which are then clustered on the cell surface by a magnetic field. This allows for rapid synthesis and characterization of a small number of single-signal nanoparticles which can be systematically combined to explore and optimize T cell activation. By increasing cognate T cell enrichment and incorporating additional costimulatory molecules using this platform, we find significantly higher frequencies and numbers of cognate T cells stimulated from an endogenous population. The magnetic field-induced association of separate particles thus provides a tool for optimizing T cell activation for adoptive immunotherapy and other immunological studies.

Entities:  

Keywords:  CD8+ T cell; Immunotherapy; artificial antigen presenting cell; immune synapse; magnetic clustering; nanoparticle

Mesh:

Substances:

Year:  2018        PMID: 29488768      PMCID: PMC6707078          DOI: 10.1021/acs.nanolett.7b05284

Source DB:  PubMed          Journal:  Nano Lett        ISSN: 1530-6984            Impact factor:   11.189


  38 in total

1.  Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres.

Authors:  Steffen Walter; Leah Herrgen; Oliver Schoor; Gundram Jung; Dorothee Wernet; Hans-Jörg Bühring; Hans-Georg Rammensee; Stefan Stevanović
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

2.  CD28 signals in the immature immunological synapse.

Authors:  Pietro G Andres; Kimberly C Howland; Douglas Dresnek; Samuel Edmondson; Abul K Abbas; Matthew F Krummel
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

3.  The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells.

Authors:  Guoxing Zheng; Bin Wang; Aoshuang Chen
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

Review 4.  HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement.

Authors:  Mathias Oelke; Jonathan P Schneck
Journal:  Clin Immunol       Date:  2004-03       Impact factor: 3.969

5.  Mechanics of receptor-mediated endocytosis.

Authors:  Huajian Gao; Wendong Shi; Lambert B Freund
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-22       Impact factor: 11.205

6.  4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.

Authors:  Hua Zhang; Kristen M Snyder; Megan M Suhoski; Marcela V Maus; Veena Kapoor; Carl H June; Crystal L Mackall
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

7.  Induction of T-cell activation or anergy determined by the combination of intensity and duration of T-cell receptor stimulation, and sequential induction in an individual cell.

Authors:  Tomohiro Yamamoto; Makoto Hattori; Tadashi Yoshida
Journal:  Immunology       Date:  2007-03-22       Impact factor: 7.397

8.  4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.

Authors:  J L Cannons; P Lau; B Ghumman; M A DeBenedette; H Yagita; K Okumura; T H Watts
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

9.  Cross-linking of 4-1BB activates TCR-signaling pathways in CD8+ T lymphocytes.

Authors:  Kyung-Ok Nam; Hyun Kang; Su-Mi Shin; Kwang-Hyun Cho; Byoungsuk Kwon; Byoung S Kwon; Sung-Jin Kim; Hyeon-Woo Lee
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

10.  Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells.

Authors:  Despina Rudolf; Tobias Silberzahn; Steffen Walter; Dominik Maurer; Johanna Engelhard; Dorothee Wernet; Hans-Jörg Bühring; Gundram Jung; Byoung S Kwon; Hans-Georg Rammensee; Stefan Stevanović
Journal:  Cancer Immunol Immunother       Date:  2007-07-27       Impact factor: 6.968

View more
  19 in total

1.  Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles.

Authors:  John W Hickey; Jonathan P Schneck
Journal:  J Vis Exp       Date:  2018-11-17       Impact factor: 1.355

Review 2.  Applications of molecular engineering in T-cell-based immunotherapies.

Authors:  David A McBride; Matthew D Kerr; Shinya L Wai; Nisarg J Shah
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-04-10

Review 3.  Enhancing cancer immunotherapy with nanomedicine.

Authors:  Darrell J Irvine; Eric L Dane
Journal:  Nat Rev Immunol       Date:  2020-01-31       Impact factor: 53.106

Review 4.  Biomimetic Nanotechnology toward Personalized Vaccines.

Authors:  Jiarong Zhou; Ashley V Kroll; Maya Holay; Ronnie H Fang; Liangfang Zhang
Journal:  Adv Mater       Date:  2019-06-17       Impact factor: 30.849

Review 5.  Nanoparticles for generating antigen-specific T cells for immunotherapy.

Authors:  Savannah E Est-Witte; Natalie K Livingston; Mary O Omotoso; Jordan J Green; Jonathan P Schneck
Journal:  Semin Immunol       Date:  2021-12-23       Impact factor: 11.130

6.  T cell receptor-targeted immunotherapeutics drive selective in vivo HIV- and CMV-specific T cell expansion in humanized mice.

Authors:  Mengyan Li; Scott J Garforth; Kaitlyn E O'Connor; Hang Su; Danica M Lee; Alev Celikgil; Rodolfo J Chaparro; Ronald D Seidel; R Brad Jones; Ravit Arav-Boger; Steven C Almo; Harris Goldstein
Journal:  J Clin Invest       Date:  2021-12-01       Impact factor: 14.808

7.  Engineering an Artificial T-Cell Stimulating Matrix for Immunotherapy.

Authors:  John W Hickey; Yi Dong; Jae Wook Chung; Sebastian F Salathe; Hawley C Pruitt; Xiaowei Li; Calvin Chang; Andrew K Fraser; Catherine A Bessell; Andrew J Ewald; Sharon Gerecht; Hai-Quan Mao; Jonathan P Schneck
Journal:  Adv Mater       Date:  2019-04-10       Impact factor: 30.849

8.  Efficient magnetic enrichment of antigen-specific T cells by engineering particle properties.

Authors:  John W Hickey; Ariel Y Isser; Fernando P Vicente; Samuel B Warner; Hai-Quan Mao; Jonathan P Schneck
Journal:  Biomaterials       Date:  2018-09-28       Impact factor: 12.479

Review 9.  Improving cancer immunotherapy through nanotechnology.

Authors:  Michael S Goldberg
Journal:  Nat Rev Cancer       Date:  2019-09-06       Impact factor: 60.716

10.  Biofunctional Janus particles promote phagocytosis of tumor cells by macrophages.

Authors:  Ya-Ru Zhang; Jia-Qi Luo; Jia-Xian Li; Qiu-Yue Huang; Xiao-Xiao Shi; Yong-Cong Huang; Kam W Leong; Wei-Ling He; Jin-Zhi Du
Journal:  Chem Sci       Date:  2020-05-05       Impact factor: 9.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.